Late-Onset Rhabdomyolysis in Sars-Cov-2

Su, D.; Kamangar, Nader

doi:10.1016/j.chest.2020.08.913

Chest

2020

DOI: 10.1016/j.chest.2020.08.913

|View full text |Cite

Late-Onset Rhabdomyolysis in Sars-Cov-2

D. Su¹,

Nader Kamangar²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Simvastatin

2020

Reactions Weekly

View full text Add to dashboard Cite

Rhabdomyolysis: case report A 59-year-old man developed rhabdomyolysis during treatment with simvastatin for hyperlipidaemia. * The man, who had a history of stage 0 chronic lymphocytic leukaemia, hyperlipidaemia, gastroesophageal reflux disease and previous intubation for influenza B, had been receiving simvastatin. Later, he presented to the hospital with a two-week history of generalised body aches. He was then diagnosed with hypoxia due to SARS-CoV-2 infection and was intubated. On day 16, he was extubated. On day 20, creatine kinase (CK) increased along with elevation of LDH. Urinalysis revealed trace protein and large blood with 4-5 red blood cells per high-powered field. A diagnosis of rhabdomyolysis secondary to simvastatin was made. He also required haemodialysis due to renal failure. The man's therapy with simvastatin was discontinued. CK normalised with fluid resuscitation.

show abstract

Simvastatin

2020

Reactions Weekly

View full text Add to dashboard Cite

show abstract

Rhabdomyolysis secondary to COVID-19 infection and vaccination: a review of literature

Karimi,

Faal Hamedanchi,

Ansari

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Rhabdomyolysis (RML), characterized by the breakdown of skeletal muscle fibers and the release of muscle contents into the bloodstream, has emerged as a notable complication associated with Coronavirus disease 2019 (COVID-19) infection and vaccination. Studies have reported an increased incidence of RML in individuals with severe COVID-19 infection. However, the exact mechanisms remain unclear and are believed to involve the host’s immune response to the virus. Furthermore, RML has been documented as a rare adverse event following COVID-19 vaccination, particularly with mRNA vaccines. Proposed mechanisms include immune responses triggered by the vaccine and T-cell activation against viral spike proteins. This study aims to review the current literature on the incidence, pathophysiology, clinical presentation, and outcomes of RML secondary to COVID-19 infection and vaccination. We identify common risk factors and mechanisms underlying this condition by analyzing case reports, clinical studies, and pharmacovigilance data. Our findings suggest that while RML is a relatively rare adverse event, it warrants attention due to its potential severity and the widespread prevalence of COVID-19 and its vaccines. This review underscores the need for heightened clinical awareness and further research to optimize management strategies and improve patient outcomes in this context.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Late-Onset Rhabdomyolysis in Sars-Cov-2

Cited by 2 publications

References 0 publications

Simvastatin

Simvastatin

Rhabdomyolysis secondary to COVID-19 infection and vaccination: a review of literature

Contact Info

Product

Resources

About